The Effect of Nanoliposomal Curcumin (Cur-NLPs) Proliferation Rate with Cell Counting Kit 8 (CCK-8) and PI3K expression in cervical cancer HeLa cells
Main Article Content
Abstract
INTRODUCTION
Cervical cancer is a major health problem in developing countries. Cisplatin therapy has limitations related to toxicity and drug resistance associated with activation of the PI3K/AKT/mTOR pathway. Curcumin has anticancer activity, but its bioavailability is low; therefore, it has been developed in a nanoliposomal formulation. This study aimed to evaluate the effects of curcumin nanoliposomes (Cur-NLPs) on proliferation and PI3K expression of HeLa cells.
METHODS
An experimental study was conducted using HeLa cells, divided into seven groups: negative control, cisplatin 5 µg/mL, and Cur-NLPs groups at 50, 100, 150, 200, and 250 µg/mL. Cell viability was measured using the cell counting kit-8 (CCK-8). Measurements were performed at 24 and 48 hours at a wavelength of 450 nm. Based on viability results, PI3K expression was analyzed at 48 hours using flow cytometry in five groups: negative control, cisplatin, and Cur-NLPs at 100, 150, and 200 µg/mL. Data were analyzed using one-way ANOVA followed by Games-Howell test.
RESULTS
Cur-NLPs significantly reduced HeLa cell viability at 24 and 48 hours (p<0.001). The 200 µg/mL dose showed the most optimal antiproliferative effect, with viability of 38.3% at 24 hours and 18.0% at 48 hours. PI3K expression in the Cur-NLPs group (42.49–45.03%) was lower than that in the cisplatin group (66.78%), but the difference was not statistically significant (p=0.063).
CONCLUSION
Cur-NLPs inhibited HeLa cell viability in a dose- and time-dependent manner and showed a trend toward reduced PI3K expression. Further replication and analysis of downstream PI3K markers are needed to confirm these findings.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
How to Cite
References
Choi S, Ismail A, Pappas-Gogos G, Boussios S. HPV and cervical cancer: a review of epidemiology and screening uptake in the UK. Pathogens 2023;12:298. doi: 10.3390/pathogens12020298. .
2. Ramachandran D, Dörk T. Genomic risk factors for cervical cancer. Cancers (Basel) 2021;13:5137. doi:10.3390/cancers13205137.
3. Hull1 R, Mbele M, Makhafola T, et al. Cervical cancer in low and middle-income countries (Review). Oncol Lett 2020;20:2058–74. doi:10.3892/ol.2020.11754.
4. Carmila C, Handayani AM. Pemberdayaan perempuan dalam upaya pencegahan kanker serviks di Puskesmas Muara Bungo II. [Empowering women in cervical cancer prevention at Muara Bungo II public health center.] J Akad Baiturrahim Jambi 2025;14:8–13. Indonesian.
5. Paramitha NMLD, Dewi IGASM, Paskarani PE, Winarti NW. Clinicopathologic features of carcinoma of the cervix uteri at Prof. Dr. I.G.N.G. Ngoerah hospital in 2021-2022. Indones J Cancer 2025;19:381–5. DOI: 10.33371/ijoc.v19i3.1328.
6. Massobrio R, Bianco L, Campigotto B, et al. New Frontiers in Locally Advanced cervical cancer treatment. J Clin Med 2024;13:1–19. doi:10.3390/jcm13154313.
7. Burmeister CA, Khan SF, Schäfer G, et al. Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Res 2022;13:200238. doi:10.1016/j.tvr.2022.200238.
8. Hassaniazad M, Inchehsablagh BR, Kamali H, et al. The clinical effect of nano micelles containing curcumin as a therapeutic supplement in patients with COVID-19 and the immune responses balance changes following treatment: a structured summary of a study protocol for a randomised controlled trial. Trials 2020;21:876. doi: 10.1186/s13063-020-04824-y.
9. Navaei ZN, Khalili-Tanha G, Zangouei AS, Abbaszadegan MR, Moghbeli M. PI3K/AKT signaling pathway as a critical regulator of cisplatin response in tumor cells. Oncol Res 2021;29:235–50. doi:10.3727/096504021X16196760297665.
10. Dias PF. Efek kurkumin pada kunyit (Curcuma longa) sebagai pengobatan kanker lambung. [Effect of curcumin from turmeric (Curcuma longa) in treatment of gastric cancer.] J Ilm Kesehat Sandi Husada 2020;9:860–4. DOI: 10.35816/jiskh.v10i2.426. Indonesian.
11. Sanidad KZ, Sukamtoh E, Xiao H, McClements DJ, Zhang G. Curcumin: recent advances in the development of strategies to improve oral bioavailability. Annu Rev Food Sci Technol 2019;10:597–617. doi:10.1146/annurev-food-032818-121738.
12. Yan Y, Kulsoom, Sun Y, et al. Advancing cancer therapy: nanomaterial-based encapsulation strategies for enhanced delivery and efficacy of curcumin. Mater Today Bio 2025;33:101963. doi: 10.1016/j.mtbio.2025.101963.
13. Hafez Ghoran S, Calcaterra A, Abbasi M, Taktaz F, Nieselt K, Babaei E. Curcumin-based nanoformulations: a promising adjuvant towards cancer treatment. Molecules 2022;27:5236. doi: 10.3390/molecules27165236.
14. Karimi M, Parsania M, Motakef Kazemi N, Qomi M, Hadipour Jahromy M. Curcumin nanoemulsion suppresses HPV oncogenes and inhibits cervical cancer progression: in vitro and in vivo study. Virol J 2025;22:165. doi: 10.1186/s12985-025-02738-2.
15. Zhou S, Li J, Yu J, et al. Unique flower-like Cur-metal complexes loaded liposomes for primary and metastatic breast cancer therapy. Mater Sci Eng C Mater Biol Appl 2021;121:111835. doi:10.1016/j.msec.2020.111835.
16. Zoi V, Kyritsis AP, Galani V, et al. The role of curcumin in cancer: a focus on the PI3K/Akt pathway. Cancers (Basel) 2024;16:1554. doi:10.3390/cancers16081554.
17. Sandhiutami NMD, Arozal W, Louisa M, Rahmat D, Wuyung PE. Curcumin nanoparticle enhances the anticancer effect of cisplatin by inhibiting PI3K/AKT and JAK/STAT3 pathway in rat ovarian carcinoma induced by DMBA. Front Pharmacol 2021;11:603235. doi:10.3389/fphar.2020.603235.
18. Venkatas J, Daniels A, Singh M. The optimization of curcumin-capped gold nanoparticle synthesis for FLuc-mRNA delivery to cervical cancer cells in vitro. Biointerface Res Appl Chem 2023;13:484. doi:10.33263/BRIAC135.484.
19. Yu Y, Hu T, Zhong G. Curcumin lipid nanoemulsion inhibits cervical cancer progression by upregulating metastasis-associated gene 1. Pharmacogn Mag 2025;21:1409–17. doi:10.1177/09731296251313641.
20. Arifin WN, Zahiruddin WM. Sample size calculation in animal studies using Resource equation approach. Malaysian J Med Sci 2017;24:101–5. doi.org/10.21315/mjms2017.24.5.11.
21. Zhu J, Gillissen B, Dang Tran D, et al. Inhibition of cell proliferation and cell viability by sinecatechins in cutaneous SCC cells is related to an imbalance of ROS and loss of mitochondrial membrane potential. Antioxidants 2022;11:1416. https://doi.org/ 10.3390/antiox11071416.
22. Wang M, Jiang S, Zhou L, et al. Potential mechanisms of action of curcumin for cancer prevention: focus on cellular signaling pathways and miRNAs. Int J Biol Sci 2019;15:1200-14. doi: 10.7150/ijbs.33710.